• Publications
  • Influence
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease. Expand
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease. Expand
The Cardiovascular Health Study: design and rationale.
TLDR
These examinations in CHS permit evaluation of CVD risk factors in older adults, particularly in groups previously under-represented in epidemiologic studies, such as women and the very old. Expand
Incidence of and risk factors for atrial fibrillation in older adults.
TLDR
The incidence of AF in older adults may be higher than estimated by previous population studies and left atrial size appears to be an important risk factor, and the control of blood pressure and glucose may be important in preventing the development of AF. Expand
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
TLDR
There was a significant increase in the rate ratio for myocardial infarction with COX-2 inhibitors compared with placebo, and regulatory authorities in several regions of the world have introduced warning statements and advisories to both healthcare professionals and the lay public about the use of various NSAIDs. Expand
Fundamentals of Clinical Trials
Introduction to Clinical Trials * What Is The Question? * Study Population * Basic Study Design * The Randomization Process * Blindness * Sample Size * Baseline Assessment * Recruitment of StudyExpand
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.
TLDR
This guideline provides an overview of the evidence on various established and potential stroke risk factors and provides recommendations for the reduction of stroke risk. Expand
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
TLDR
An effort to develop a tool to assess and display the position of any given trial within the pragmatic–explanatory continuum is described, intended to inform trial design rather than provide a method of classifying trials for the purpose of systematic reviews. Expand
Lipoprotein Management in Patients With Cardiometabolic Risk
TLDR
It is unclear whether lipoprotein parameters other than LDL or non-HDL cholesterol provide clinically significant additional prognostic information regarding CVD risk, yield more information about the effectiveness of therapy, or indicate more appropriate treatment targets. Expand
...
1
2
3
4
5
...